Ask about this productRelated genes to: BUB1B antibody
- Gene:
- BUB1B NIH gene
- Name:
- BUB1 mitotic checkpoint serine/threonine kinase B
- Previous symbol:
- -
- Synonyms:
- BUBR1, MAD3L, Bub1A, SSK1
- Chromosome:
- 15q15.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-25
- Date modifiied:
- 2019-04-23
Related products to: BUB1B antibody
Related articles to: BUB1B antibody
- Cervical cancer (CC) ranks as the fourth most prevalent cancer in women worldwide. While biomarkers exist, previous studies are often limited by public dataset heterogeneity, incomplete spectrum coverage, or lack of clinical validation. To address these limitations, this study aims to profile fresh tissues spanning the full continuum to systematically identify hub genes with dysregulated expression during malignant progression. - Source: PubMed
Publication date: 2026/05/20
Li PengShao YawenWang JunlingLin Ru - Letrozole is a first-line aromatase inhibitor for estrogen receptor-positive (ER +) breast cancer, yet resistance occurs in 20-30% of patients, significantly limiting therapeutic benefit. The absence of reliable pretreatment biomarkers remains a major barrier to precision therapy. This study aimed to identify robust prognostic biomarkers and elucidate molecular mechanisms underlying letrozole resistance through integrative bioinformatics, molecular docking, and cell-based functional assays. Weighted gene co-expression network analysis of transcriptomic datasets revealed a module strongly associated with nonresponse. From this, seven candidate genes (BUB1B, CENPU, KIF11, RRM2, NUSAP1, TRIP13, PRC1) were identified as significantly overexpressed in tumors and consistently correlated with poor survival in ER + breast cancer. Among them, RRM2 emerged as the most clinically relevant marker. Molecular docking demonstrated a potential competitive interaction between RRM2 and letrozole, implicating disruption of aromatase inhibition and DNA replication pathways in resistance, while functional assays in ER + cell lines showed that RRM2 modulates proliferation and MYC-CCND1 signaling. Validation in an independent letrozole-treated cohort confirmed the strong prognostic value of RRM2. These findings provide novel mechanistic insights into endocrine resistance and establish RRM2 as a pivotal prognostic biomarker and therapeutic target. This work offers a strong foundation for biomarker-guided strategies to optimize treatment and overcome resistance in ER + breast cancer. - Source: PubMed
Publication date: 2026/05/21
Hung Wan-YuHuang Shih-ChunChen Shou-TungLin Chi-ChenHou Ming-Hon - Human aneuploid conception, a leading cause of infertility, pregnancy loss, and congenital disorders (e.g. Down's syndrome), arises from errors in chromosome segregation during oocyte meiosis or embryonic mitosis. While advanced maternal age is a well-established risk factor, significant inter-individual variation exists among younger women, suggesting a substantial role for maternal genetic determinants. - Source: PubMed
Publication date: 2026/05/13
Ha SiyaoLiu WenyiYuan PingYuan ShangyaCao ChunweiMeng AnmingChen Hui - Triple-negative breast cancer (TNBC) is frequently characterized by notably elevated Ki-67 expression, a hallmark of uncontrolled rapid cell-cycle progression. However, the underlying mechanisms remain unclear, leading to limited therapeutic options. - Source: PubMed
Publication date: 2026/04/22
Liu NianqiuZhu MengdiCai ZijieWang JingruCao WeihanShi QianfengWang LinghanJiang XiaotingZhou JingLin JinnaYang WangGan HuipeiNie JianyunLiu Qiang - Environmental and chemical exposures are major yet incompletely characterized drivers of human carcinogenesis. Aflatoxin, a potent food-borne mycotoxin, has been implicated in tumor initiation, proliferation, and immune suppression in intrahepatic cholangiocarcinoma (ICC), but its genomic mechanisms remain poorly defined. - Source: PubMed
Publication date: 2026/03/31
Li FengpingMa YuanyangCheng YanZou Shanshan